论文部分内容阅读
目的评估无痛性血尿患者尿脱落细胞CK20表达的检测在诊断膀胱癌的前瞻性研究中的价值。方法采用双盲法检测59例无痛性血尿患者尿脱落细胞CK20mRNA的表达,另取20例正常对照标本。分析参数包括肿瘤数目、大小、病理和CK20mRNA标志物。结果17例CK20阳性者中病理活检确诊15例为膀胱癌。该项检测具极高的特异性(90·91%)及阳性预报值(88·24%)。在复发病例中阳性率(58·82%)比初发者中(25·00%)明显要高,P=0·0498。CK20表达与肿瘤分级间无明显相关性。结论CK20阳性表达在血尿患者膀胱癌诊断预测中极具价值。
Objective To evaluate the value of urine CK20 expression in painless hematuria in the prospective study of bladder cancer. Methods The expression of CK20mRNA in urine exfoliated cells from 59 patients with painless hematuria was detected by double-blind method. Another 20 normal controls were selected. Analytical parameters include tumor size, size, pathology, and CK20 mRNA markers. Results Of the 17 cases of CK20 positive pathological biopsy confirmed 15 cases of bladder cancer. The test was highly specific (90.91%) and positive predictive value (88.24%). The positive rate (58.82%) in the recurrent cases was significantly higher than that in the initial (25.00%), P = 0.0989. There was no significant correlation between CK20 expression and tumor grade. Conclusion The positive expression of CK20 is of great value in the diagnosis of bladder cancer in hematuria patients.